Introduction {#sec1}
============

The morphan (2-azabicyclo\[3.3.1\]nonane) skeleton widely exists in biologically active natural and natural-like synthetic products. For example, strychnine^[@ref1]^ and morphine^[@ref2]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) are the best known molecules due to their broad biological profile. In addition, some synthetic pharmaceuticals or natural-like biological molecules, such as immune suppressants (FR901483),^[@ref3]^ antitumor agents (daphniphyllum alkaloids),^[@ref4]^ opioid agonists (compound **A**),^[@ref5]^ and opioid receptor antagonists (e.g., compound **B**([@ref6]) and naloxone), are morphan derivatives.

![Structures of morphans and the targeted compounds.](ao-2018-007268_0011){#fig1}

Available morphan derivatives have been a concern for many years due to their broad spectrum of biological activities. Consequently, in recent years, more and more practical procedures have been developed for the synthesis of various morphan derivatives by the organic chemists.^[@ref7]−[@ref12]^ These procedures have greatly contributed to synthesis of natural-like morphan products. However, most of these approaches involve metal catalysts under strict anhydrous conditions or multistep synthesis. Accordingly, it is necessary and desirable to develop concise, highly site-selective cascade reaction to construct a library of molecularly diverse morphan derivatives.

Quinone monoketals are an important building block that are widely used for the synthesis of various structurally diverse natural or natural-like products.^[@ref13],[@ref14]^ Quinone monoketals contain two unsaturated C=C bonds, which are often used as 1,4-nucleophilic addition acceptors by one of the two C=C bonds for the synthesis of fused-ring compounds.^[@ref15],[@ref16]^ Compared with quinone monoketals, quinone imine ketals^[@ref17],[@ref18]^ have some of their own properties, such as having a more active imino group that is attacked by alkyne or alkyl amino, like the 1,2-addition, or one of the two C=C bonds as in the Diels--Alder reaction. However, the two C=C bonds of quinone imine ketals are hardly used as 1,4-nucleophilic addition acceptors. For many years, only a few successful examples have been completed.^[@ref18]^

Enaminones and enamine esters are interesting and versatile building blocks^[@ref19]−[@ref24]^ that are used unparalleled to synthesize various fused heterocycles by the thousands. However, the enaminones and enamine esters used as substrates to construct bridged ring compounds are very limited. To date, incorporation at the two nucleophilic sites (α-C and N) through the Michael/aza-Michael addition or the aza-Michael/1,2-addition reaction of enaminones or enamine esters to form bridged ring frame morphan compounds has been very limited.

For many years, 1,1-enediamines^[@ref25]−[@ref35]^ have been widely used as building blocks. Among them, some morphan derivatives have been designed and synthesized on the basis of 1,1-enediamines.^[@ref36],[@ref37]^ However, despite being versatile building blocks, enaminones and enamine esters have not been widely used in the synthesis of bridged ring compounds, such as morphan derivatives whose reactivity is usually lower than that of 1,1-enediamines.

To prepare molecularly diverse morphan derivatives starting with the less reactive enaminones and enamine esters substrates and to further investigate the more active immunosuppressant, we study the reactions of different types of quinone monoketals **1** or quinone imine ketals **2** with enaminones or enamine esters **3**--**4** under special conditions. We obtained novel target morphan compounds **5**--**7** by the Michael and aza-Michael reaction of quinone monoketals **1** or quinone imine ketals **2** with enaminones or enamine esters **3**--**4** promoted by 1,8-diazabicyclo\[5.4.0\]undec-7-ene (DBU) in acetone at reflux. Unexpectedly, when the cyclic enaminone **4** was used as a substrate for the reaction with quinone monoketals **1**, they produced special morphans **8** by the aza-Michael reaction and 1,2-addition reaction ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).

![Synthesis Routes of Morphans **5**--**8**](ao-2018-007268_0003){#sch1}

Results and Discussion {#sec2}
======================

Initially, to evaluate the Michael and aza-Michael addition of quinone monoketals **1** and Enaminones **3**, the mixture (**1a**/**3a** = 1.1:1) was treated in acetonitrile at reflux for 12 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1) and the reaction could not proceed. Then, proton acids, including AgOTf and Cu(OTf)~2~, were added into the mixture (**1a**/**3a** = 1.1:1) at reflux for 12 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--3). The results demonstrated that the reaction could not proceed at all. Then, K~2~CO~3~ was added into the mixture with the same solvent and refluxed for 12 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 4); we luckily obtained the product with a 33% yield. Thereafter, different solvents, including acetonitrile, 1,4-dioxane and acetone, were used as solvent and promoted by the inorganic base Cs~2~CO~3.~ The results showed that Cs~2~CO~3~ can promote the reaction to some extent. Then, a stronger alkali *t*-BuOK was used with 1,4-dioxane at reflux for 12 h. The results indicated that the reaction becomes more complex and cannot achieve a positive result as the alkali is too strong ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 7). Then, the organic base DBU was added with different solvents and the mixture was refluxed for 12 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--11). Fortunately, we found that the organic base DBU can largely promote the reaction and produce the product with excellent yield in acetone (90%). Subsequently, other organic bases, including Et~3~N and DABCO, were evaluated in acetone at reflux for 12 h and showed that DABCO and Et~3~N also could not produce a positive result ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 12--13). On the basis of these results, we concluded that DBU is the optimal promoter and acetone is the best solvent for this cascade reaction ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 10). Finally, the different reaction time was also investigated ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 14--15). The results revealed that the optimal reaction conditions for the synthesis of morphan derivatives were acetone as the solvent and DBU as the base under reflux for 12 h with a 90% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 10).

###### Optimization of the Reaction Conditions for the Model Reaction[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-007268_0005){#fx1}

  entry   solvent                                       promoter     *t* (°C)     time (h)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------- --------------------------------------------- ------------ ------------ ---------- -------------------------------------------
  1       CH~3~CN                                                    reflux       12         nr
  2       CH~3~CN                                       AgOTf        reflux       12         nr
  3       CH~3~CN                                       Cu(OTf)~2~   reflux       12         nr
  4       CH~3~CN                                       K~2~CO~3~    reflux       12         33
  5       CH~3~CN                                       Cs~2~CO~3~   reflux       12         62
  6       1,4-dioxane                                   Cs~2~CO~3~   reflux       12         68
  7       1,4-dioxane                                   *t*-BuOK     reflux       12         complex
  8       CH~3~CN                                       DBU          reflux       12         82
  9       1,4-dioxane                                   DBU          reflux       12         nr
  10      **acetone**[c](#t1fn3){ref-type="table-fn"}   **DBU**      **reflux**   **12**     **90**
  11      EtOH                                          DBU          reflux       12         12
  12      acetone                                       DABCO        reflux       12         nr
  13      acetone                                       Et~3~N       reflux       12         nr
  14      acetone                                       DBU          reflux       8          85
  15      acetone                                       DBU          reflux       16         89

Reaction conditions: **1a** (1.1 mmol), **3a** (1.0 mmol), base (2.0 mmol), solvent (15 mL).

Isolated yield based on **3a**. nr = no reaction.

Bold entry indicates the best condition.

We further explored the scope and limitations of the cascade reaction based on the optimal conditions. Therefore, different quinone monoketals **1** and various enaminones **3** were utilized in this cascade reaction ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **5a**--**u**). The results showed that various enaminones are suitable for the reaction to obtain the target compounds with moderate to good yields. However, the structure of quinone monoketals **1** has influence on the reaction yield ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **5a** vs **f**; **5l** vs **t**). Similarly, the structure of enaminones **3** also determines the reaction yield. Usually, the electron-withdrawing (F, Cl) benzoyl group of enaminones is favorable to the yield ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **5a** vs **c**; **5q** vs **r**).

###### Michael and Aza-Michael Reaction for the Synthesis of Morphans **5**[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2018-007268_0006){#fx2}

Reaction conditions: **1** (1.1 mmol), **3** (1.0 mmol), DBU (2.0 mmol), acetone (15 mL).

Isolated yield based on **3**.

To further explore the scope and limitations of the cascade reaction, the different enamine esters **3** were used as substrates to react with quinone monoketals **1** in acetone ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). The results showed that many kinds of enamine esters are a good substrate and produce the target compounds with good yields. Among them, on using (*E*)-3-aminobut-2-enenitrile as a substrate, the reaction can generate the products with excellent yields ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, **6d** vs **b**). On the basis of the reaction of the different quinone monoketals **1** with diverse enaminones and enamine esters **3**, the quinone imine ketal **2** were used in this reaction and the scope and limitations of the cascade reaction were evaluated ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). The results showed that the cascade reaction can smoothly proceed under the same conditions and produce the target compounds with good yields. Remarkably, we only obtain one of the isomers of **7a**--**e** ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}).

###### Michael and Aza-Michael Addition for the Synthesis of Morphans **6**[a](#t3fn1){ref-type="table-fn"}^,^[b](#t3fn2){ref-type="table-fn"}
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Reaction conditions: **1** (1.1 mmol), **3** (1.0 mmol), DBU (2.0 mmol), acetone (15 mL).

Isolated yield based on **3**.

###### Michael and Aza-Michael Addition for the Synthesis of Morphans **7**[a](#t4fn1){ref-type="table-fn"}^,^[b](#t4fn2){ref-type="table-fn"}

![](ao-2018-007268_0008){#fx4}

Reaction conditions: **2** (1.1 mmol), **3** (1.0 mmol), DBU (2.0 mmol), acetone (15 mL).

Isolated yield based on **3**.

To achieve the molecular diversity of the products, cyclic enaminone **4** was used as a substrate in reactions with quinone monoketals **1a**--**b**. Surprisingly, we obtained another kind of morphan derivatives **8a**--**b** with moderate yields (63--66%). The reaction was via the aza-Michael reaction and 1,2-addition reaction. First, the amino group of the enaminones binds to one of the C=C bonds of the quinone monoketals **1** through the aza-Michael reaction. Second, the α-C of the enaminones attack the carbonyl of compounds **1** via 1,2-addition to form the target compounds ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}, **8a**--**b**). Since the amino group of **4** is more active than that of α-C in the cyclic enaminone **4**, it leads to different products via different reactions.

###### Michael and Aza-Michael Addition for the Synthesis of Morphans **8**[a](#t5fn1){ref-type="table-fn"}^,^[b](#t5fn2){ref-type="table-fn"}

![](ao-2018-007268_0009){#fx5}

Reaction conditions: **1** (1.1 mmol), **4** (1.0 mmol), DBU (2.0 mmol), acetone (15 mL).

Isolated yield based on **4**.

To confirm the structure of the morphan derivatives, compounds **5n**, **6e**, **7b**, and **8a** were selected as the representative compounds and each was characterized by X-ray crystallography, as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} (**5n**: CCDC 1817955; **6e**: CCDC 1817956) and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} (**7b**: CCDC 1818163; **8a**: CCDC 1818117).

![X-ray crystal structure of **5n** (left) and **6e** (right) (ellipsoids are drawn at the 30% probability level).](ao-2018-007268_0001){#fig2}

![X-ray crystal structure of **7b** (left) and **8a** (right) (ellipsoids are drawn at the 30% probability level).](ao-2018-007268_0002){#fig3}

A proposed mechanism of how DBU promoted the Michael and aza-Michael addition reactions is presented in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Initially, the quinone imine ketals **2** react with the enaminones **3** via Michael addition to obtain the intermediate **9**. Then, intermediate compounds **9** are inverted to give intermediates **10** through imine-enamine tautomerization. Finally, intermediates **10** underwent intramolecular aza-Michael addition to form the target compounds **7**.

![Mechanism Hypotheses of the Cascade Reaction](ao-2018-007268_0004){#sch2}

Conclusions {#sec3}
===========

In conclusion, we developed a procedure for concise synthesis of potentially biologically active morphan derivatives through the Michael and aza-Michael addition or aza-Michael and 1,2-addition reactions. Accordingly, a molecularly diverse morphan library was rapidly constructed in one-pot with good yields by simply refluxing a reaction mixture of quinone monoketals **1** or quinone imine ketals **2** and enaminones or enamine esters **3**--**4** in acetone and promoted by DBU.

Experimental Section {#sec4}
====================

General Methods {#sec4.1}
---------------

All compounds were fully characterized by spectroscopic data analysis. The NMR spectra were recorded on a Bruker DRX500 or DRX600 NMR spectrophotometer (Bruker Biospin GmbH, Ettlingen, Germany); chemical shifts (δ) are expressed in ppm, *J* values are given in Hz, and deuterated dimethyl sulfoxide (DMSO)-*d*~6~ or CDCl~3~ was used as solvent. The IR spectra were recorded on a Fourier transform infrared (FT-IR) Avatar 360 spectrophotometer (Thermo Nicolet Corp., Madison WI) using the KBr pellet technique. The reactions were monitored by thin-layer chromatography (TLC) using silica gel GF~254~ (EMD Millipore, Billerica, MA). The melting points were determined on an XT-4A melting point apparatus and are uncorrected. High-resolution mass spectra time-of-flight (HRMS-TOF) were performed on an AutoSpec Premier P776 mass spectrometer (Waters Corp., Milford,. MA). X-ray diffraction analysis was performed using an Apex Duo diffractometer (Bruker AXS GmbH., Karlsruhe, Germany). All chemicals and solvents were used as received without further purification unless otherwise stated. Column chromatography was performed on silica gel (200--300 mesh).

The materials were purchased from Adamas-β Ltd. (Shanghai China). Compounds **1** were prepared according to the literature.^[@ref17]^ Compounds **2** were prepared according to the literature.^[@ref38]^

General Procedure for the Synthesis of Compounds **5**--**6** {#sec4.2}
-------------------------------------------------------------

The quinone monoketals **1** (1.1 mmol), enaminones or enamine esters **3** (1.0 mmol), and acetone (15 mL) were charged into a 25 mL round-bottomed flask. Then, DBU (2.0 mmol) was added into the mixture. The mixture was held at reflux for about 12 h and monitored by TLC until the enaminones or enamine esters **3** substrates were completely consumed. After the reaction was completed, the reaction system was cooled to room temperature. The reaction mixture was then poured into 25 mL of water and 50 mL of ethyl acetate for extraction and separation. Subsequently, the crude product was concentrated by distillation under reduced pressure and then purified by column chromatography (petroleum ether/ethyl acetate = 1: 2) and a series of compounds **5**--**6** were obtained with a 61--96% yield. The products were further identified by NMR spectroscopy, FT-IR spectroscopy, and HRMS analysis.

### (1*R*,5*R*)-4-(4-Fluorobenzoyl)-9,9-dimethoxy-2-(*p*-tolyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5a**) {#sec4.2.1}

Yellow solid; yield: 368 mg, 90%; mp 187.9 °C; IR (KBr): 2945, 2836, 1720, 1570, 1510, 1251, 817, 602, 419 cm^--1^; ^1^H NMR (600 MHz, DMSO-*d*~6~): δ = 2.26--2.28 (m, 3H, CH~3~), 2.28--2.32 (m, 1H, COCH~2~), 2.46--2.52 (m, 1H, COCH~2~), 2.87--2.90 (m, 1H, COCH~2~CHN), 2.95--2.99 (m, 1H, COCH~2~CHN), 3.15 (s, 3H, CH~3~O), 3.44 (s, 3H, CH~3~O), 3.50--3.55 (m, 1H, CH), 4.50--4.55 (m, 1H, CH~2~CHN), 7.02--7.04 (m, 2H, ArH), 7.16--7.18 (m, 2H, ArH), 7.26 (s, 1H, CHN), 7.27--7.28 (m, 2H, ArH), 7.48--7.51 (m, 2H, ArH); ^13^C NMR (150 MHz, DMSO-*d*~6~): δ = 20.7, 20.7, 33.7, 43.4, 44.2, 49.0, 49.1, 57.4, 97.6, 113.9, 115.7 (d, *J* = 21.0 Hz), 119.7, 130.7, 131.1 (d, *J* = 7.5 Hz), 134.6, 136.8, 141.7, 145.2, 163.6 (d, *J* = 246.0 Hz), 190.8, 208.4; ^19^F NMR (560 MHz, DMSO-*d*~6~): δ = −110.3; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~FNO~4~ \[M + H\]^+^, 410.1762; found, 410.1761.

### (1*R*,5*R*)-4-(4-Fluorobenzyl)-9,9-dimethoxy-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5b**) {#sec4.2.2}

Brown solid; yield: 391 mg, 92%; mp 190.6 °C; IR (KBr): 2834, 1720, 1562, 1509, 1436, 1248, 1147, 829, 600 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.60--2.67 (m, 2H, COCH~2~), 2.87--2.91 (m, 2H, COCH~2~CHN), 3.28 (s, 3H, CH~3~O), 3.48 (s, 3H, CH~3~O), 3.77 (s, 3H, OCH~3~Ar), 3.75--3.79 (m, 1H, CH), 4,20--4.24 (m, 1H, CH~2~CHN), 6.85--6.87 (m, 2H, ArH), 6.93--6.95 (m, 2H, ArH), 7.03--7.06 (m, 2H, ArH), 7.16 (s, 1H, CHN), 7.48--7.54 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 33.4, 43.4, 43.9, 49.0, 49.0, 55.6, 59.0, 97.6, 113.4, 115.1, 122.6, 130.6 (d, *J* = 8.8 Hz), 136.4, 137.8, 146.5, 157.7, 162.9, 164.9, 191.4, 208.7; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~FNO~5~ \[M + H\]^+^, 426.1711; found, 426.1710.

### (1*R*,5*R*)-4-(4-Chlorobenzoyl)-9,9-dimethoxy-2-(*p*-tolyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5c**) {#sec4.2.3}

Yellow solid; yield: 375 mg, 88%; mp 223.5--224.0 °C; IR (KBr): 3446, 2975, 2928, 1715, 1577, 1511, 1399, 1114, 839, 761 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.15--2.10 (s, 3H, CH~3~), 2.20--2.25 (m, 1H, COCH~2~), 2.38--2.44 (m, 1H, COCH~2~), 2.79--2.82 (m, 1H, COCH~2~CHN), 2.87--2.88 (m, 1H, COCH~2~CHN), 3.07 (s, 3H, CH~3~O), 3.36 (s, 3H, CH~3~O), 3.41--3.46 (m, 1H, CH), 4.41--4.46 (m, 1H, CH~2~CHN), 6.96--6.97 (m, 2H, ArH), 7.09--7.10 (m, 2H, ArH), 7.21 (s, 1H, CHN), 7.36--7.37 (m, 2H, ArH), 7.42--7.44 (m, 2H, ArH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 20.7, 20.7, 33.6, 43.4, 44.2, 49.0, 49.1, 57.4, 97.6, 113.8, 119.8, 128.9, 130.5, 130.7, 134.7, 135.4, 139.1, 141.7, 145.4, 190.8, 208.4; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~ClNO~4~ \[M + H\]^+^, 426.1467; found, 426.1467.

### (1*R*,5*R*)-4-(4-Chlorobenzoyl)-9,9-dimethoxy-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5d**) {#sec4.2.4}

Yellow solid; yield: 380 mg, 86%; mp 197.9 °C; IR (KBr): 3445, 1716, 1572, 1511, 1390, 1249, 1150, 831, 456 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.59--2.62 (m, 2H, COCH~2~), 2.87--2.91 (m, 2H, COCH~2~CHN), 3.28 (s, 3H, CH~3~O), 3.48 (s, 3H, CH~3~O), 3.75--3.76 (m, 1H, CH), 3.78 (s, 3H, OCH~3~Ar), 4.20--4.24 (m, 1H, CH~2~CHN), 6.85--6.87 (m, 2H, ArH), 6.93--6.95 (m, 2H, ArH), 7.15 (s, 1H, CHN), 7.33--7.34 (m, 2H, ArH), 7.42--7.43 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 33.4, 43.4, 43.9, 49.0, 49.0, 55.6, 59.0, 97.5, 113.4, 115.1, 122.7, 128.3, 129.9, 136.2, 137.7, 138.6, 146.7, 157.7, 191.3, 208.6; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~ClNO~5~ \[M + H\]^+^, 442.1416; found, 442.1424.

### (1*R*,5*R*)-9,9-Diethoxy-4-(4-fluorobenzoyl)-2-(4-fluorophenyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5e**) {#sec4.2.5}

Yellow solid; yield: 353 mg, 80%; mp 185.4 °C; IR (KBr): 3446, 2982, 2930, 1720, 1573, 1509, 1249, 1146, 841, 599 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.13--1.16 (m, 3H, CH~3~CH~2~O), 1.31--1.33 (m, 3H, CH~3~CH~2~O), 2.59--2.62 (m, 2H, COCH~2~), 2.91--2.97 (m, 2H, COCH~2~CHN), 3.41--3.65 (m, 4H, CH~2~O), 3.69--3.74 (m, 1H, CH), 4.24--4.28 (m, 1H, CH~2~CHN), 6.94--7.11 (m, 6H, ArH), 7.17 (s, 1H, CHN), 7.49--7.54 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.2, 15.3, 34.3, 43.4, 44.1, 56.9, 56.9, 59.6, 97.1, 115.2 (d, *J* = 21.3 Hz), 116.7 (d, *J* = 22.5 Hz), 122.2 (d, *J* = 8.8 Hz), 130.7 (d, *J* = 8.8 Hz), 136.2, 140.9, 145.6, 160.2 (d, *J* = 245.0 Hz), 164.0 (d, *J* = 248.8 Hz), 191.6, 208.6; HRMS (TOF EI^+^): *m*/*z* calcd. for C~25~H~26~F~2~NO~4~ \[M + H\]^+^, 442.1824; found, 442.1824.

### (1*R*,5*R*)-9,9-Diethoxy-4-(4-fluorobenzoyl)-2-(*p*-tolyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5f**) {#sec4.2.6}

Yellow solid; yield: 328 mg, 75%; mp 79.5 °C; IR (KBr): 3728, 3441, 2975, 2926, 1720, 1598, 1391, 1249, 766, 603 cm^--1^; H NMR (500 MHz, DMSO-*d*~6~): δ = 1.03--1.05 (m, 3H, CH~3~CH~2~O), 1.26--1.29 (m, 3H, CH~3~CH~2~O), 2.25--2.27 (m, 3H, CH~3~), 2.28--2.32 (m, 1H, COCH~2~), 2.45--2.49 (m, 1H, COCH~2~), 2.87--2.91 (m, 1H, COCH~2~CHN), 2.97--3.01 (m, 1H, COCH~2~CHN), 3.30--3.35 (m, 1H, CH), 3.48--3.56 (m, 2H, CH~2~O), 3.72--3.76 (m, 2H, CH~2~O), 4.48--4.52 (m, 1H, CH~2~CHN), 6.99--7.02 (m, 2H, ArH), 7.15--7.20 (m, 2H, ArH), 7.25--7.27 (m, 2H, ArH), 7.28 (s, 1H, CHN), 7.47--7.50 (m, 2H, ArH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.6, 15.6, 20.7, 20.7, 34.5, 43.5, 44.4, 56.8, 56.9, 58.0, 97.3, 114.1, 115.7 (d, *J* = 21.3 Hz), 119.5, 130.7, 131.1 (d, *J* = 8.8 Hz), 134.5, 136.9 (d, *J* = 2.5 Hz), 141.9, 145.1, 163.7 (d, *J* = 246.3 Hz), 190.8, 208.5; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −110.3; HRMS (TOF EI^+^): *m*/*z* calcd. for C~26~H~29~FNO~4~ \[M + H\]^+^, 438.2075; found, 438.2074.

### (1*R*,5*R*)-9,9-Diethoxy-4-(4-fluorobenzoyl)-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5g**) {#sec4.2.7}

Brown solid; yield: 317 mg, 70%; mp 148.3 °C; IR (KBr): 3445, 2980, 1719, 1572, 1511, 1436, 1249, 1147, 836, 558 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.14--1.17 (m, 3H, CH~3~CH~2~O), 1.30--1.33 (m, 3H, CH~3~CH~2~O), 2.59--2.62 (m, 2H, COCH~2~), 2.90--2.94 (m, 2H, COCH~2~CHN), 3.46--3.49 (m, 1H, CH), 3.60--3.63 (m, 2H, CH~2~O), 3.69--3.74 (m, 2H, CH~2~O), 3.81 (s, 3H, CH~3~O), 4,21--4.25 (m, 1H, CH~2~CHN), 6.84--6.86 (m, 2H, ArH), 6.92--6.94 (m, 2H, ArH), 7.15 (s, 1H, CHN), 7.32--7.34 (m, 2H, ArH), 7.41--7.43 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.3, 34.1, 43.5, 44.1, 55.6, 56.8, 56.9, 59.8, 97.2, 113.7, 115.1, 122.6, 128.3, 129.9, 136.1, 137.9, 138.7, 146.7, 157.6, 191.3, 208.9; HRMS (TOF EI^+^): *m*/*z* calcd. for C~26~H~29~FNO~5~ \[M + H\]^+^, 454.2024; found, 454.2025.

### (1*R*,5*R*)-4-(4-Chlorobenzoyl)-9,9-diethoxy-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5h**) {#sec4.2.8}

Yellow solid; yield: 305 mg, 65%; mp 138.0 °C; IR (KBr): 3445, 1717, 1574, 1511, 1437, 1248, 1148, 832, 555 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.14--1.17 (m, 3H, CH~3~CH~2~O), 1.30--1.33 (m, 3H, CH~3~CH~2~O), 2.59--2.62 (m, 2H, COCH~2~), 2.89--2.94 (m, 2H, COCH~2~CHN), 3.46--3.49 (m, 1H, CH), 3.60--3.63 (m, 2H, CH~2~O), 3.71--3.74 (m, 2H, CH~2~O), 3.74 (s, 3H, CH~3~OAr), 4,20--4.24 (m, 1H, CH~2~CHN), 6.84--6.86 (m, 2H, ArH), 6.92--6.93 (m, 2H, ArH), 7.03--7.06 (m, 2H, ArH), 7.15 (s, 1H, CHN), 7.47--7.50 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.3, 34.2, 43.5, 44.1, 55.6, 56.9, 59.8, 97.2, 113.8, 115.0, 115.2, 122.5, 130.6, 136.5, 138.0, 146.5, 157.6, 162.9, 164.8, 191.4, 209.0; HRMS (TOF EI^+^): *m*/*z* calcd. for C~26~H~29~ClNO~5~ \[M + H\]^+^, 470.1729; found, 470.1729.

### (1*R*,5*R*)-2-Benzyl-4-(4-chlorobenzoyl)-9,9-dimethoxy-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5i**) {#sec4.2.9}

Yellow liquid; yield: 332 mg, 78%; IR (KBr): 3446, 2943, 1716, 1577, 1398, 1360, 1113, 1009, 698 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.42--2.56 (m, 2H, COCH~2~), 2.73--2.85 (m, 2H, COCH~2~CHN), 3.03 (s, 3H, CH~3~O), 3.38 (s, 3H, CH~3~O), 3.61--3.65 (m, 1H, CH), 3.67--3.72 (m, 1H, CH~2~CHN), 4.27 (s, 2H, ArH), 6.97 (s, 1H, CHN), 7.21--7.37 (m, 9H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 33.2, 43.0, 44.1, 48.6, 48.9, 56.2, 58.2, 97.5, 110.3, 128.2, 128.3, 128.6, 129.0, 129.8, 135.0, 135.8, 138.8, 150.1, 190.6, 209.8; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~ClNO~4~ \[M + H\]^+^, 426.1467; found, 426.1465.

### (1*R*,5*R*)-2,4-Dibenzyl-9,9-dimethoxy-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5j**) {#sec4.2.10}

Yellow liquid; yield: 289 mg, 74%; IR (KBr): 3727, 3446, 2922, 1716, 1582, 1439, 1212, 1112, 701, 557 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.41--2.44 (m, 1H, COCH~2~), 2.55--2.58 (m, 1H, COCH~2~), 2.71--2.75 (m, 1H, COCH~2~CHN), 2.80--2.84 (m, 1H, COCH~2~CHN), 3.03 (s, 3H, CH~3~O), 3.36 (s, 3H, CH~3~O), 3.60--3.65 (m, 1H, CH), 3.70--3.71 (m, 1H, CH~2~CHN), 4.25 (s, 2H, CH~2~Ar), 7.03 (s, 1H, CHN), 7.20--7.21 (m, 2H, ArH), 7.29--7.37 (m, 6H, ArH), 7.40--7.42 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 33.1, 43.0, 44.1, 48.6, 48.9, 56.0, 58.1, 97.5, 110.2, 128.0, 128.2, 128.3, 128.5, 129.0, 129.7, 135.2, 140.5, 150.3, 192.0, 209.1; HRMS (TOF EI+): *m*/*z* calcd. for C~24~H~26~NO~4~ \[M + H\]^+^, 392.1856; found, 392.1864.

### (1*R*)-4-(4-Chlorobenzoyl)-9,9-diethoxy-2-(4-fluorobenzyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5k**) {#sec4.2.11}

Yellow liquid; yield: 330 mg, 70%; IR (KBr): 3446, 2975, 2928, 1715, 1577, 1511, 1399, 1114, 839, 761 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.12--1.14 (m, 3H, CH~3~CH~2~O), 1.24--1.27 (m, 3H, CH~3~CH~2~O), 2.40--2.44 (m, 1H, COCH~2~), 2.52--2.55 (m, 1H, COCH~2~), 2.73--2.77 (m, 1H, COCH~2~CHN), 2.90--2.95 (m, 1H, COCH~2~CHN), 3.29--3.32 (m, 1H, CH), 3.45--3.54 (m, 2H, CH~2~O), 3.57--3.61 (m, 1H, CH~2~CHN), 3.67--3.72 (m, 2H, CH~2~O), 4.22--4.25 (m, 2H, CH~2~Ar), 6.92 (s, 1H, CHN), 7.03--7.06 (m, 2H, ArH), 7.21--7.26 (m, 2H, ArH), 7.31--7.35 (m, 3H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.2, 15.2, 33.8, 43.0, 44.2, 56.5, 56.7, 57.3, 96.9, 110.6, 115.7, 115.9, 128.3, 129.7 (d, *J* = 6.3 Hz), 131.1 (d, *J* = 3.8 Hz), 135.9, 138.8, 150.1, 162.7 (d, *J* = 246.3 Hz), 190.6; HRMS (TOF EI^+^): *m*/*z* calcd. for C~26~H~28~ClFNO~4~ \[M + H\]^+^, 472.1685; found, 472.1688.

### (1*R*,5*R*)-2-Benzyl-4-(4-chlorobenzoyl)-9,9-diethoxy-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5l**) {#sec4.2.12}

Yellow liquid; yield: 295 mg, 65%; IR (KBr): 3726, 3446, 2973, 2928, 1717, 1576, 1439, 1115, 876 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.10--1.13 (m, 3H, CH~3~CH~2~O), 1.23--1.26 (m, 3H, CH~3~CH~2~O), 2.42--2.45 (m, 1H, COCH~2~), 2.52--2.55 (m, 1H, COCH~2~), 2.73--2.77 (m, 1H, COCH~2~CHN), 2.88--2.92 (m, 1H, COCH~2~CHN), 3.23--3.25 (m, 1H, CH), 3.43--3.55 (m, 2H, CH~2~O), 3.63 (m, 1H, CH~2~CHN), 3.66--3.71 (m, 2H, CH~2~Ar), 6.96 (s, 1H, CHN), 7.23--7.37 (m, 9H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.2, 15.2, 33.9, 43.1, 44.2, 56.4, 56.7, 57.3, 58.1, 97.0, 110.4, 127.5, 128.0, 128.4, 128.9, 130.0, 135.2, 135.7, 138.9, 150.3, 190.5, 209.4; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~25~ClNO~4~ \[M + H\]^+^, 426.1467; found, 426.1468.

### (1*R*,5*R*)-4-Benzoyl-2-benzyl-9,9-diethoxy-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5m**) {#sec4.2.13}

Yellow liquid; yield: 331 mg, 79%; IR (KBr): 3726, 3446, 2974, 2926, 1717, 1583, 1212, 1113, 700, 584 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.11--1.13 (m, 3H, CH~3~CH~2~O), 1.23--1.26 (m, 3H, CH~3~CH~2~O), 2.41--2.45 (m, 1H, COCH~2~), 2.55--2.58 (m, 1H, COCH~2~), 2.72--2.76 (m, 1H, COCH~2~CHN), 2.89--2.93 (m, 1H, COCH~2~CHN), 3.23--3.26 (m, 1H, CH), 3.46--3.55 (m, 2H, CH~2~O), 3.60--3.65 (m, 1H, CH~2~CHN), 3.68--3.72 (m, 2H, CH~2~O), 4.26 (s, 2H, CH~2~N), 7.00 (s, 1H, CHN), 7.23--7.41 (m, 10H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.2, 15.2, 33.8, 43.1, 44.3, 56.4, 56.6, 57.2, 58.0, 97.1, 110.4, 128.0, 128.0, 128.3, 128.3, 128.8, 129.7, 135.4, 140.6, 150.5, 192.0, 209.5; HRMS (TOF EI^+^): *m*/*z* calcd. for C~26~H~30~NO~4~ \[M + H\]^+^, 420.2169; found, 420.2170.

### (1*R*,5*R*)-4-(4-Fluorobenzoyl)-9,9-dimethoxy-2-phenethyl-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5n**) {#sec4.2.14}

Yellow solid; yield: 300 mg, 71%; mp 200.0--200.5 °C; IR (KBr): 3445, 1717, 1574, 1511, 1437, 1248, 1148, 832, 555 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.49--2.55 (m, 2H, COCH~2~), 2.78--2.90 (m, 4H, COCH~2~CHN, CH~2~Ar), 3.22--3.24 (m, 1H, CH), 3.28 (s, 3H, CH~3~O), 3.39--3.43 (m, 1H, CH~2~CHN), 3.45 (s, 3H, CH~3~O), 3.66--3.71 (m, 1H, CH~2~N), 6.51 (s, 1H, CHN), 6.89--6.93 (m, 2H, ArH), 7.10--7.12 (m, 2H, ArH), 7.17--7.19 (m, 2H, ArH), 7.24--7.32 (m, 3H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 32.9, 35.4, 43.7, 44.0, 48.7, 48.9, 56.1, 57.4, 97.4, 109.1, 114.8 (d, *J* = 21.3 Hz), 126.8, 128.7, 129.2, 130.3 (d, *J* = 7.5 Hz), 136.3, 137.8, 150.2, 163.5 (d, *J* = 247.5 Hz), 190.1, 209.0; HRMS (TOF EI^+^): *m*/*z* calcd. for C~25~H~27~FNO~4~ \[M + H\]^+^, 424.1919; found, 424.1917.

### (1*R*,5*R*)-9,9-Diethoxy-4-(4-fluorobenzoyl)-2-phenethyl-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5o**) {#sec4.2.15}

Yellow liquid; yield: 338 mg, 75%; IR (KBr): 3726, 3446, 2975, 2928, 1715, 1600, 1563, 1454, 1114, 701 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.22--1.25 (m, 3H, CH~3~CH~2~O), 1.30--1.33 (m, 3H, CH~3~CH~2~O), 2.51--2.54 (m, 2H, COCH~2~), 2.77--2.81 (m, 4H, COCH~2~CHN, CH~2~Ar), 3.26--3.48 (m, 2H, CH~2~O), 3.58--3.64 (m, 3H, CH~2~O, CH~2~N), 3.64--3.68 (m, 1H, CH), 3.69--3.73 (m, 1H, CH~2~CHN), 3.79--3.85 (m, 1H, CH~2~N), 6.51 (s, 1H, CHN), 6.89--6.92 (m, 2H, ArH), 7.11--7.13 (m, 2H, ArH), 7.20--7.21 (m, 2H, ArH), 7.27--7.32 (m, 3H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.4, 33.7, 35.3, 43.7, 44.2, 55.9, 56.7, 56.7, 58.1, 97.1, 114.7, 114.9, 126.8, 128.7, 129.2, 130.4 (d, *J* = 8.8 Hz), 136.4, 137.9, 150.5, 163.5 (d, *J* = 247.5 Hz), 190.1, 209.4; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −111.1; HRMS (TOF EI^+^): *m*/*z* calcd. for C~27~H~31~FNO~4~ \[M + H\]^+^, 452.2232; found, 452.2232.

### (1*R*,5*R*)-4-(4-Chlorobenzoyl)-2-(4-chlorophenethyl)-9,9-diethoxy-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5p**) {#sec4.2.16}

Yellow solid; yield: 401 mg, 80%; mp 75.6 °C; IR (KBr): 3725, 3445, 2975, 2927, 1715, 1576, 1399, 1200, 1114, 839 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.16--1.25 (m, 3H, CH~3~CH~2~O), 1.30--1.33 (m, 3H, CH~3~CH~2~O), 2.47--2.53 (m, 2H, COCH~2~), 2.75--2.81 (m, 2H, COCH~2~CHN), 2.93--2.97 (m, 1H, CH~2~Ar), 3.21--3.26 (m, 1H, CH~2~Ar), 3.36--3.41 (m, 1H, CH~2~N), 3.58--3.69 (m, 5H, CH~2~N, CH~2~O, CH~2~O, CH), 3.79--3.83 (m, 1H, CH~2~CHN), 6.39--6.43 (m, 1H, CHN), 7.04--7.06 (m, 2H, ArH), 7.14--7.15 (m, 2H, ArH), 7.24--7.29 (m, 4H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.4, 33.5, 34.7, 43.7, 44.2, 55.7, 56.7, 56.7, 58.2, 97.1, 109.5, 128.2, 128.8, 129.5, 130.7, 132.8, 135.6, 136.3, 138.6, 150.3, 190.2, 209.2; HRMS (TOF EI^+^): *m*/*z* calcd. for C~27~H~30~Cl~2~NO~4~ \[M + H\]^+^, 502.1546; found, 502.1544.

### (1*R*,5*R*)-4-(4-Chlorobenzoyl)-9,9-diethoxy-2-(4-methoxyphenethyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5q**) {#sec4.2.17}

Yellow solid; yield: 343 mg, 69%; mp 140.3 °C; IR (KBr): 3445, 1709, 1552, 1511, 1455, 1202, 1103, 826, 775 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.23--1.26 (m, 3H, CH~3~CH~2~O), 1.30--1.33 (m, 3H, CH~3~CH~2~O), 2.48--2.53 (m, 2H, COCH~2~), 2.72--2.82 (m, 3H, COCH~2~CHN, CH~2~Ar), 2.91--2.95 (m, 1H, CH~2~Ar), 3.23--3.26 (m, 1H, CH~2~N), 3.35--3.38 (m, 1H, CH~2~N), 3.57--3.66 (m, 5H, CH~2~O, CH~2~O, CH), 3.80--3.82 (m, 1H, CH~2~CHN), 3.83 (s, 3H, OCH~3~), 6.45 (s, 1H, CHN), 6.84--6.85 (m, 2H, ArH), 7.04--7.11 (m, 4H, ArH), 7.19--7.21 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.4, 33.5, 34.5, 43.8, 44.2, 55.2, 56.2, 56.7, 56.7, 58.3, 97.1, 109.2, 114.1, 128.0, 129.7, 130.2, 135.4, 138.7, 150.6, 158.6, 190.1, 209.3; HRMS (TOF EI^+^): *m*/*z* calcd. for C~28~H~33~ClNO~5~ \[M + H\]^+^, 498.2042; found, 498.2043.

### (1*R*,5*R*)-4-Benzoyl-9,9-diethoxy-2-(4-methoxyphenethyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5r**) {#sec4.2.18}

Yellow liquid; yield: 402 mg, 87%; IR (KBr): 3424, 3278, 1718, 1625, 1556, 1514, 1360, 1245, 1074, 757 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.22--1.32 (m, 6H, CH~3~CH~2~O), 2.47--2.55 (m, 2H, COCH~2~), 2.71--2.80 (m, 3H, COCH~2~CHN, CH~2~Ar), 2.92--2.96 (m, 1H, CH~2~Ar), 3.20--3.23 (m, 1H, COCH~2~CHN), 3.31--3.35 (m, 1H, CH), 3.6 (s, 3H, OCH~3~), 3.67--3.71 (m, 1H, CHN), 3.80--3.83 (m, 4H, CH~2~O), 3.80--3.83 (m, 4H, CH~2~O), 6.56 (s, 1H, CHN), 6.83--6.84 (m, 2H, ArH), 7.09--7.27 (m, 6H, ArH), 7.31--7.34 (m, 1H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.3, 15.4, 33.5, 34.5, 43.8, 44.2, 55.2, 56.1, 56.7, 56.7, 58.1, 97.2, 109.4, 114.1, 127.8, 128.3, 129.5, 129.8, 130.1, 140.4, 150.6, 158.5, 191.4, 209.5; HRMS (TOF EI^+^): *m*/*z* calcd. for C~28~H~34~NO~5~ \[M + H\]^+^, 464.2431; found, 464.2432.

### (1*R*,5*R*)-2-(4-Chlorobenzyl)-4-(4-fluorobenzoyl)-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]-dioxolan\]-3-en-7-one (**5s**) {#sec4.2.19}

Yellow liquid; yield: 291 mg, 66%; IR (KBr): 3424, 3278, 1718, 1625, 1556, 1514, 1360, 1245, 1074, 757 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.26--2.29 (m, 1H, COCH~2~), 2.37--2.40 (m, 1H, COCH~2~), 2.79--2.80 (m, 1H, COCH~2~CHN), 2.94--2.95 (m, 1H, COCH~2~CHN), 3.09--3.10 (m, 1H, CH), 3.47--3.51 (m, 1H, CH~2~CHN), 3.63--3.65 (m, 1H, CH~2~O), 3.99--4.02 (m, 1H, CH~2~O), 4.04--4.08 (m, 2H, CH~2~O), 4.39--4.42 (m, 1H, CH~2~N), 4.52--4.55 (m, 1H, CH~2~N), 7.18--7.22 (m, 2H, ArH), 7.27 (s, 1H, CHN), 7.32--7.35 (m, 2H, ArH), 7.44--7.47 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 35.9, 43.8, 45.0, 57.2, 58.3, 65.2, 65.4, 104.9, 110.7, 115.9 (d, *J* = 22.5 Hz), 128.3, 129.4 (d, *J* = 8.8 Hz), 129.8, 131.0 (d, *J* = 2.5 Hz), 135.9, 138.7, 149.6, 162.7 (d, *J* = 245.0 Hz), 190.7, 208.4; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~22~ClFNO~4~ \[M + H\]^+^, 442.1216; found,442.1215.

### (1*R*,5*R*)-2-Benzyl-4-(4-chlorobenzoyl)-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**5t**) {#sec4.2.20}

Yellow liquid; yield: 296 mg, 70%; IR (KBr): 3424, 3278, 1718, 1625, 1556, 1514, 1360, 1245, 1074, 757 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.31--2.32 (m, 1H, COCH~2~), 2.43--2.46 (m, 1H, COCH~2~), 2.84--2.88 (m, 1H, COCH~2~CHN), 2.99--3.30 (m, 1H, COCH~2~CHN), 3.13--3.17 (m, 1H, CH), 3.54--3.58 (m, 1H, CHN), 3.68--3.73 (m, 1H, CH~2~CH~2~), 4.03--4.13 (m, 1H, CH~2~CH~2~), 4.45--4.48 (m, 1H, CH~2~Ar), 4.59--4.62 (m, 1H, CH~2~Ar), 7.32--7.44 (m, 8H, ArH), 7.48--7.52 (m, 1H, ArH), 7.51 (s, 1H, CHN); ^13^C NMR (125 MHz, CDCl~3~): δ = 36.0, 43.8, 45.0, 58.0, 58.3, 65.1, 65.4, 104.9, 110.5, 127.8, 128.2, 128.4, 128.9, 129.8, 135.1, 135.8, 138.8, 149.9, 190.7, 208.6; HRMS (TOF EI^+^): *m*/*z* calcd. for C~24~H~23~ClNO~4~ \[M + H\]^+^, 424.1310; found, 424.1310.

### (1*R*,5*R*)-4-(4-Fluorobenzoyl)-9-methoxy-9-methyl-2-(4-methylbenzyl)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**5u**) {#sec4.2.21}

Yellow liquid; yield: 248 mg, 61%; mp 165.6 °C; IR (KBr): 3445, 2926, 1712, 1571, 1510, 1252, 1154, 765, 504 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.77 (s, 3H, CH~3~), 2.30 (s, 3H, CH~3~Ar), 2.66--2.74 (m, 2H, COCH~2~), 2.75--2.78 (m, 2H, COCH~2~CHN), 3.25 (s, 3H, CH~3~), 3.64--3.65 (m, 1H, CH), 4.09--4.13 (m, 1H, CHN), 6.89--6.90 (m, 2H, ArH), 7.03--7.07 (m, 2H, ArH), 7.11--7.13 (m, 2H, ArH), 7.28 (s, 1H, CHN), 7.49--7.52 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 18.5, 20.7, 34.1, 44.2, 44.3, 49.7, 63.1, 71.2, 113.2, 115.1 (d, *J* = 21.3 Hz), 120.9, 130.3, 130.7 (d, *J* = 7.5 Hz), 135.4, 136.4, 142.4, 146.4, 163.9 (d, *J* = 247.5 Hz), 191.7, 208.0; HRMS (TOF EI^+^): *m*/*z* calcd. for C~25~H~27~FNO~3~ \[M + H\]^+^, 408.1969; found, 408.1968.

### (1*R*,5*R*)-Ethyl 9,9-dimethoxy-7-oxo-3-(trifluoromethyl)-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**6a**) {#sec4.2.22}

Yellow solid; yield: 269 mg, 80%; mp 77.3 °C; IR (KBr): 3446, 2975, 1691, 1468, 1399, 1187, 1129, 925, 790, 436 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.24--1.27 (m, 3H, CH~3~), 2.40--2.48 (m, 2H, COCH~2~), 2.77--2.82 (m, 2H, COCH~2~CHN), 3.32 (s, 3H, OCH~3~), 3.42 (s, 3H, OCH~3~), 3.44--3.48 (m, 1H, CH), 3.89--3.93 (m, 1H, CH~2~CHN), 4.12--4.21 (m, 2H, CH~2~O), 5.29 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 13.9, 36.2, 43.1, 46.0, 48.6, 49.0, 50.7, 60.5, 96.0, 101.0, 120.4 (q, *J* = 274.6 Hz), 138.5 (q, *J* = 33.8 Hz), 164.9, 208.7; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −64.0; HRMS (TOF EI^+^): *m*/*z* calcd. for C~14~H~19~F~3~NO~5~ \[M + H\]^+^, 338.1210; found, 338.1213.

### (1*R*,5*R*)-Ethyl 9,9-dimethoxy-3-methyl-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**6b**) {#sec4.2.23}

Yellow solid; yield: 232 mg, 82%; mp 77.3 °C; IR (KBr): 3446, 2975, 1691, 1468, 1399, 1187, 1129, 925, 790, 436 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.23--1.25 (m, 3H, CH~3~CH~2~), 2.19 (s, 3H, CH~3~), 2.34--2.37 (m, 1H, COCH~2~), 2.45--2.48 (m, 1H, COCH~2~), 2.73--2.80 (m, 2H, COCH~2~CHN), 3.30 (s, 3H, OCH~3~), 3.40 (s, 3H, OCH~3~), 3.75--3.79 (m, 1H, CH), 4.06--4.12 (m, 2H, CH~2~), 4.78--4.79 (m, 2H, CHN); ^13^C NMR (125 MHz, CDCl~3~): δ = 14.5, 20.8, 29.6, 35.5, 44.1, 46.8, 48.6, 50.4, 51.4, 59.0, 94.6, 97.0, 129.9, 143.4, 152.0, 167.4, 210.7; HRMS (TOF EI^+^): *m*/*z* calcd. for C~14~H~22~NO~5~ \[M + H\]^+^, 284.1492; found, 284.1494.

### (1*R*,5*R*)-Isopropyl 9,9-dimethoxy-3-methyl-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**6c**) {#sec4.2.24}

Yellow liquid; yield: 267 mg, 90%; IR (KBr): 3725, 3386, 2959, 2834, 1715, 1526, 1245, 1087, 976, 816 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.23--1.25 (m, 3H, CH~3~CH~2~O), 2.19 (s, 3H, CH~3~), 2.34--2.37 (m, 1H, COCH~2~), 2.45--2.48 (m, 1H, COCH~2~), 2.73--2.80 (m, 2H, COCH~2~CHN), 3.30 (s, 3H, CH~3~O), 3.36--3.40 (m, 1H, CH), 3.75--3.79 (m, 1H, CH~2~CHN), 4.06--4.12 (m, 2H, CH~2~O), 4.78--4.79 (m, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 14.5, 20.8, 35.5, 44.1, 46.8, 48.6, 48.7, 51.4, 59.0, 94.6, 97.0, 152.0, 167.4, 210.7; HRMS (TOF EI^+^): *m*/*z* calcd. for C~15~H~24~NO~5~ \[M + H\]^+^, 298.1649; found, 298.1652.

### (1*R*,5*R*)-9,9-Dimethoxy-3-methyl-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carbonitrile (**6d**) {#sec4.2.25}

Yellow liquid; yield: 226 mg, 96%; IR (KBr): 3362, 2920, 2184, 1716, 1612, 1531, 1401, 1101, 420 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.99 (s, 3H, CH~3~), 2.35--2.38 (m, 1H, COCH~2~), 2.49--2.52 (m, 1H, COCH~2~), 2.74--2.78 (m, 2H, COCH~2~CHN), 2.88--2.92 (m, 1H, CH), 3.34 (s, 3H, OCH~3~), 3.38 (s, 3H, OCH~3~), 3.80--3.84 (m, 1H, CHN), 5.10--5.11 (m, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 18.9, 36.7, 43.7, 46.3, 48.8, 50.4, 51.1, 75.4, 96.1, 121.5, 152.4, 208.8; HRMS (TOF EI^+^): *m*/*z* calcd. for C~12~H~17~N~2~O~3~ \[M + H\]^+^, 237.1234; found, 237.1234.

### (1*R*,5*R*)-Ethyl 9,9-diethoxy-7-oxo-3-(trifluoromethyl)-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**6e**) {#sec4.2.26}

Yellow solid; yield: 321 mg, 88%; mp 116.5 °C; IR (KBr): 3370, 2983, 2936, 1720, 1671, 1612, 1518, 1404, 1167, 830 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.17--1.20 (m, 3H, CH~3~), 1.22--1.30 (m, 6H, CH~3~CH~2~O), 2.40--2.48 (m, 2H, COCH~2~), 2.79--2.85 (m, 2H, COCH~2~CHN), 3.45--3.49 (m, 1H, CH), 3.56--3.72 (m, 4H, CH~2~O), 3.85--3.89 (m, 1H, CH~2~CHN), 4.12--4.20 (m, 2H, CH~2~), 5.01 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 13.9, 15.2, 15.2, 36.8, 43.1, 46.1, 51.5, 51.5, 56.9, 60.5, 95.7, 101.5, 120.5 (q, *J* = 273.8 Hz), 138.4 (q, *J* = 33.8 Hz), 164.9, 208.7; HRMS (TOF EI^+^): *m*/*z* calcd. for C~16~H~23~F~3~NO~5~ \[M + H\]^+^, 366.1523; found, 366.1524.

### (1*R*,5*R*)-9,9-Diethoxy-3-methyl-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carbonitrile (**6f**) {#sec4.2.27}

Yellow liquid; yield: 242 mg, 92%; IR (KBr): 3375, 2927, 2930, 2184, 1716, 1612, 1528, 1401, 1101, 420 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.21--1.23 (m, 3H, CH~3~CH~2~O), 1.25--1.28 (m, 3H, CH~3~CH~2~O), 1.98 (s, 3H, CH~3~), 2.33--2.36 (m, 1H, COCH~2~), 2.49--2.52 (m, 1H, COCH~2~), 2.76--2.81 (m, 1H, COCH~2~CHN), 2.88--2.92 (m, 1H, CH), 3.60--3.67 (m, 4H, CH~2~O), 3.77--3.81 (m, 1H, CHN), 4.78 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.2, 15.3, 18.9, 37.5, 43.8, 46.5, 52.1, 56.6, 56.7, 75.9, 95.8, 121.5, 152.1, 208.9; HRMS (TOF EI^+^): *m*/*z* calcd. for C~14~H~21~N~2~O~3~ \[M + H\]^+^, 265.1547; found, 265.1548.

General Procedure for the Synthesis of Compounds **7** {#sec4.3}
------------------------------------------------------

The quinone monoketals **1** (1.1 mmol), enamine esters **3** (1.0 mmol), and acetone (15 mL) were charged into a 25 mL round-bottomed flask. Then DBU (2.0 mmol) was added into the mixture. The mixture was at reflux for about 12 h. After the reaction was completed, the reaction system was cooled to room temperature. The reaction mixture was poured into 25 mL of water and 50 mL of ethyl acetate for extraction and separation. Then, the crude product was concentrated by distillation under reduced pressure, which was purified by column chromatography (petroleum ether/ethyl acetate = 1: 2) and a series of compounds **7** with 87--92% yields was obtained.

### *tert*-Butyl-((1*R*,5*R*)-4-(4-fluorobenzoyl)-2-(4-fluorophenyl)-9,9-dimethoxy-2-azabicyclo\[3.3.1\]-nona-3,6-dien-7-yl)carbamate (**7a**) {#sec4.3.1}

Yellow solid; yield: 455 mg, 89%; mp 222.7--223.2 °C; IR (KBr): 3430, 3254, 3056, 1729, 1562, 1506, 1230, 1145, 770 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.46 (s, 9H, CH~3~), 2.26--2.29 (m, 1H, CH~2~CHN), 2.71--2.72 (m, 1H, CH~2~CHN), 3.11 (s, 3H, OCH~3~), 3.35 (s, 3H, OCH~3~), 3.52--3.53 (m, 1H, CH), 4.32--4.33 (m, 1H, CHN), 5.95--5.99 (m, 1H, CHCH), 6.4 (br, 1H, NH), 7.01--7.02 (m, 4H, ArH), 7.05--7.09 (m, 2H, ArH), 7.22 (s, 1H, CHC), 7.52--7.56 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 28.3, 31.5, 35.2, 48.6, 49.6, 56.0, 60.4, 80.6, 97.4, 100.4, 115.1 (d, *J* = 21.3 Hz), 115.6, 116.5 (d, *J* = 22.5 Hz), 120.8 (d, *J* = 8.75 Hz), 130.7 (d, *J* = 7.5 Hz), 136.7 (d, *J* = 3.8 Hz), 137.6, 141.0, 145.6, 152.2, 159.8 (d, *J* = 243.8 Hz), 163.9 (d, *J* = 248.8 Hz), 192.1. HRMS (TOF EI^+^): *m*/*z* calcd. for C~28~H~31~F~2~N~2~O~5~ \[M + H\]^+^, 513.2196; found, 513.2194.

### *tert*-Butyl((1*R*,5*R*)-4-(4-fluorobenzoyl)-9,9-dimethoxy-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]nona-3,6-dien-7-yl)carbamate (**7b**) {#sec4.3.2}

Yellow solid; yield: 471 mg, 90%; mp 238.2--238.7 °C; IR (KBr): 3261, 2965, 2837, 1732, 1509, 1326, 1233, 1070, 768 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.46 (s, 9H, CH~3~), 2.27--2.30 (m, 1H, CH~2~CHN), 2.69--2.73 (m, 1H, CH~2~CHN), 3.12 (s, 3H, OCH~3~), 3.36 (s, 3H, OCH~3~), 3.51--3.52 (m, 1H, CH), 3.78 (s, 3H, OCH~3~Ar), 4.31--4.32 (m, 1H, CHN), 6.06--6.10 (m, 1H, CHCH), 6.35 (br, 1H, NH), 6.83--6.86 (m, 2H, ArH), 6.99--7.07 (m, 2H, ArH), 7.23 (s, 1H, CHC), 7.52--7.55 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 28.5, 31.4, 34.8, 48.4, 49.4, 55.4, 55.8, 79.3, 97.5, 101.2, 115.0, 115.4, 115.6 (d, *J* = 21.3 Hz), 120.6, 131.0 (d, *J* = 8.8 Hz), 137.5, 138.0, 138.5, 145.3, 152.9, 156.6, 163.4 (d, *J* = 245.0 Hz), 190.9. HRMS (TOF EI^+^): *m*/*z* calcd. for C~29~H~34~FN~2~O~6~ \[M + H\]^+^, 525.2395; found, 525.2392.

### *tert*-Butyl((1*R*,5*R*)-4-(4-chlorobenzoyl)-9,9-dimethoxy-2-phenyl-2-azabicyclo\[3.3.1\]nona-3,6-dien-7-yl)carbamate (**7c**) {#sec4.3.3}

Yellow liquid; yield: 456 mg, 87%; IR (KBr): 3425, 3062, 1727, 1539, 1497, 1240, 1147, 1051, 760 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.46 (s, 9H, CH~3~), 2.27--2.30 (m, 1H, CH~2~CHN), 2.71--2.72 (m, 1H, CH~2~CHN), 3.10 (s, 3H, OCH~3~), 3.36 (s, 3H, OCH~3~), 3.51--3.52 (m, 1H, CH), 4.42--4.43 (m, 1H, CHN), 5.96--6.00 (m, 1H, CHCH), 6.38 (br, 1H, NH), 7.04--7.06 (m, 2H, ArH), 7.27 (s, 1H, CHC), 7.31--7.37 (m, 4H, ArH), 7.48--7.49 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 28.3, 31.7, 35.1, 48.6, 49.6, 55.4, 80.5, 97.4, 100.7, 115.6, 118.7, 124.5, 128.3, 129.8, 130.0, 136.1, 137.5, 139.0, 144.4, 145.6, 152.2, 192.2. HRMS (TOF EI^+^): *m*/*z* calcd. for C~28~H~32~ClN~2~O~5~ \[M + H\]^+^, 511.1994; found, 511.1994.

### *tert*-Butyl((1*R*,5*R*)-4-(4-chlorobenzoyl)-9,9-dimethoxy-2-(*p*-tolyl)-2-azabicyclo\[3.3.1\]nona-3,6 -dien-7-yl)carbamate (**7d**) {#sec4.3.4}

Yellow solid; yield: 456 mg, 87%; mp 243.5--244.0 °C; IR (KBr): 3265, 2969, 1726, 1512, 1430, 1391, 1245, 1150, 762 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.38 (s, 9H, CH~3~), 2.25 (s, 3H, CH~3~), 2.25 (s, 1H, CH~2~CHN), 3.00 (s, 3H, OCH~3~), 3.23--3.27 (m, 1H, CH), 3.36 (s, 3H, OCH~3~), 4.44--4.46 (m, 1H, CHN), 6.15--6.19 (m, 1H, CHCH), 7.02--7.04 (m, 2H, ArH), 7.15--7.17 (m, 2H, ArH), 7.23 (br, 1H, NH), 7.44--7.48 (m, 4H, ArH), 8.58 (s, 1H, CHC); ^13^C NMR (125 MHz, CDCl~3~): δ = 20.7, 28.5, 31.5, 34.7, 48.4, 49.4, 55.0, 79.3, 97.4, 101.2, 115.5, 118.7, 128.8, 130.5, 130.7, 133.8, 135.1, 138.5, 139.6, 142.0, 145.0, 152.9, 191.1. HRMS (TOF EI^+^): *m*/*z* calcd. for C~29~H~34~ClN~2~O~5~ \[M + H\]^+^, 525.2151; found, 525.2150.

### *tert*-Butyl-((1*R*,5*R*)-4-(4-chlorobenzoyl)-9,9-dimethoxy-2-(4-methoxyphenyl)-2-azabicyclo\[3.3.1\]nona-3,6-dien-7-yl)carbamate (**7e**) {#sec4.3.5}

Yellow solid; yield: 496 mg, 92%; mp 136.2 °C; IR (KBr): 3351, 2833, 1732, 1509, 1434, 1389, 1238, 1148, 762 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.46 (s, 9H, CH~3~), 2.27--2.30 (m, 1H, CH~2~CHN), 2.70--2.73 (m, 1H, CH~2~CHN), 3.12 (s, 3H, OCH~3~), 3.36 (s, 3H, OCH~3~), 3.51--3.52 (m, 1H, CH), 3.78 (s, 3H, OCH~3~Ar), 4.31--4.32 (m, 1H, CHN), 6.03--6.07 (m, 1H, CHCH), 6.35 (br, 1H, NH), 6.84--6.85 (m, 2H, ArH), 6.99--7.01 (m, 2H, ArH), 7.27 (s, 1H, CHC), 7.33--7.35 (m, 2H, ArH), 7.46--7.48 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 28.3, 31.5, 35.2, 48.6, 49.6, 55.6, 56.2, 80.5, 97.5, 100.8, 114.7, 114.9, 121.0, 128.3, 130.0, 135.9, 137.5, 138.2, 139.2, 146.4, 152.3, 157.0, 191.8. HRMS (TOF EI^+^): *m*/*z* calcd. for C~29~H~34~ClN~2~O~6~ \[M + H\]^+^, 541.2100; found, 541.2101.

General Procedure for the Synthesis of Compounds **8** {#sec4.4}
------------------------------------------------------

The quinone monoketals **1** (1.1 mmol), enaminones **4** (1.0 mmol), and acetone (15 mL) were charged into a 25 mL round-bottomed flask. Then, DBU (2.0 mmol) was added into the mixture. The mixture was at reflux for about 12 h. After the reaction was completed, the reaction system was cooled to room temperature. The reaction mixture was poured into 25 mL of water and 50 mL of ethyl acetate for extraction and separation. Then, the crude product was concentrated by distillation under reduced pressure, which was purified by column chromatography (petroleum ether/ethyl acetate = 1: 2) and a series of compounds **8** with 63--66% yields were obtained.

### (2*S*,6*S*)-6-Hydroxy-3,3-dimethoxy-2,3,6,8,9,10-hexahydro-2,6-methanobenzo\[*b*\]azocin-7(1*H*)-one (**8a**) {#sec4.4.1}

Yellow liquid; yield: 175 mg, 66%; IR (KBr): 3414, 3233, 2943, 1617, 1528, 1428, 1343, 1121, 770 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.63--1.66 (m, 1H, CH~2~), 1.72--1.73 (m, 1H, CH~2~), 1.78--1.79 (m, 1H, CH~2~NH), 2.09--2.11 (m, 1H, CH~2~NH), 2.13--2.15 (m, 1H, CH~2~NH), 2.35--2.40 (m, 2H, CH~2~C), 3.11 (s, 3H, OCH~3~), 3.21 (s, 3H, OCH~3~), 3.72--3.76 (m, 1H, CHN), 5.43--5.46 (m, 1H, CH~3~C), 5.89--5.92 (m, 1H, CHC), 7.70 (br, 1H, NH), 7.93 (br, 1H, OH); ^13^C NMR (125 MHz, CDCl~3~): δ = 21.7, 27.9, 33.6, 36.5, 47.9, 48.9, 52.0, 69.0, 99.9, 106.7, 121.3, 140.9, 160.6, 194.1. HRMS (TOF EI^+^): *m*/*z* calcd. for C~14~H~18~NO~4~ \[M -- H^+^\], 264.1241; found, 264.1241.

### (2*S*,6*S*)-3,3-Diethoxy-6-hydroxy-2,3,6,8,9,10-hexahydro-2,6-methanobenzo\[*b*\]azocin-7(1*H*)-one (**8b**) {#sec4.4.2}

Yellow liquid; yield: 184 mg, 63%; IR (KBr): 3414, 3240, 2971, 1617, 1379, 1191, 1010, 605 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.01--1.11 (m, 3H, CH~3~CH~2~O), 1.12--1.15 (m, 3H, CH~3~CH~2~O), 1.62--1.65 (m, 1H, CH~2~), 1.71--1.80 (m, 2H, CH~2~, CH~2~CH), 2.07--2.17 (m, 3H, CH~2~CH, CH~2~CO), 2.32--2.43 (m, 2H, CH, CHC), 3.37--3.50 (m, 3H, CH~2~O, CH~2~O), 3.59--3.62 (m, 1H, CH~2~O), 5.41--5.43 (s, 1H, CH), 5.85--5.87 (s, 1H, CH), 7.69 (br, 1H, OH), 7.85 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.8, 15.8, 21.7, 27.9, 33.7, 36.5, 52.8, 55.3, 56.5, 69.0, 99.8, 106.8, 122.4, 140.3, 160.6, 194.1. HRMS (TOF EI^+^): *m*/*z* calcd. for C~16~H~22~NO~4~ \[M -- H^+^\], 292.1554; found, 292.1555.
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